Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study
To assess present angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) use among patients with proteinuric chronic kidney disease (CKD) and examine barriers limiting this guideline-concordant care.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Ian E. McCoy, Jialin Han, Maria E. Montez-Rath, Glenn M. Chertow Tags: Original article Source Type: research